Long-term follow-up of women in trials of adjuvant therapy for breast cancer: Is it still important?

Journal of Clinical Oncology

Volumn 29, Issue 13, 2011, Pages 1651-1652

  Pritchard, Kathleen I ^a   Sousa, Berta ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; AROMATASE INHIBITOR; LIPOPROTEIN A; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG COST; EARLY CANCER; EDITORIAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HAZARD RATIO; HEART PROTECTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; THERAPY EFFECT;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 79955603819     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.2766     Document Type: Editorial

References (16)

1. Hackshaw A, Roughton M, Forsyth S, et al: Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 29:1657-1663, 2010
2. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group: Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer: Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. J Natl Cancer Inst 88:1834-1839, 1996
3. Ewer MS, Glück S: A woman's heart: The impact of adjuvant endocrine therapy on cardiovascular health. Cancer 115:1813-1826, 2009
4. Love RR, Wiebe DA, Feyzi JM, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86:1534-1539, 1994 (Pubitemid 24330218)
5. Stamatelopoulos KS, Lekakis JP, Poulakaki NA, et al: Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 147:1093-1099, 2004 (Pubitemid 38880970)
6. Costantino JP, Kuller LH, Ives DG, et al: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89:776-782, 1997 (Pubitemid 27242278)
7. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: The Scottish Cancer Trials Breast Group. BMJ 311:977-980, 1995
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
9. Fisher B, Constantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 97:1652-1662, 2005 (Pubitemid 41672231)
10. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406, 1993 (Pubitemid 23264348)
11. Nordenskjöld B, Rosell J, Rutqvist LE, et al: Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial. J Natl Cancer Inst 97:1609-1610, 2005 (Pubitemid 41662715)
12. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989 (Pubitemid 19034031)
13. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
14. Mouridsen H, Keshaviah A, Coates AS, et al: Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715-5722, 2007
15. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, et al: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643, 2006
16. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005 (Pubitemid 41535367)